Akari Therapeutics (Nasdaq:AKTX) - Prezzo delle azioni, notizie e analisi

AKTX Panoramica delle azioni

Akari Therapeutics, Plc, azienda biofarmaceutica in fase clinica, si concentra sullo sviluppo di terapie avanzate per malattie autoimmuni e infiammatorie. Maggiori dettagli

AKTX analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Analisi del rischio

Patrimonio netto negativo

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Non ha una capitalizzazione di mercato significativa ( $16M )

+ 1 più rischio

Akari Therapeutics, Plc Concorrenti

HST Global

OTCPK:HSTC

US$14.7m

NanoViricides

NYSEAM:NNVC

US$19.7m

OpGen

OTCPK:OPGN

US$12.5m

Aprea Therapeutics

NasdaqCM:APRE

US$15.7m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Akari Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.30
Massimo di 52 settimane	US$4.40
Minimo di 52 settimane	US$1.08
Beta	0.95
1Variazione di 1 mese	-45.02%
Variazione a 3 mesi	-65.79%
Variazione di 1 anno	-56.81%
3Variazione a 3 anni	-96.13%
Variazione a 5 anni	-96.84%
Variazione dall'IPO	-99.74%

Notizie e aggiornamenti recenti

Recent updates

Akari Therapeutics GAAP EPS of $0.00

Sep 27

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Sep 20

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Jul 28

Akari Therapeutics GAAP EPS of $0.00

Jul 20

Patient completes course with Akari's stem cell transplant related complication treatment

Jul 07

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Dec 31

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Apr 28

Akari Therapeutics reports FY results

Apr 21

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

Mar 15

Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease

Dec 03

Rendimenti per gli azionisti

	AKTX	US Biotechs	US Mercato
7D	-37.5%	2.5%	2.2%
1Y	-56.8%	16.1%	31.6%

Ritorno vs Industria: AKTX ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 16.1 % nell'ultimo anno.

Rendimento vs Mercato: AKTX ha avuto una performance inferiore al mercato US che ha registrato un rendimento 31.6 % nell'ultimo anno.

Volatilità dei prezzi

Is AKTX's price volatile compared to industry and market?
AKTX volatility
AKTX Average Weekly Movement	14.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di AKTX è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 14% ) di AKTX è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	7	Samir Patel	www.akaritx.com

Akari Therapeutics, Plc, azienda biofarmaceutica in fase clinica, si concentra sullo sviluppo di terapie avanzate per malattie autoimmuni e infiammatorie. Il suo candidato principale è il nomacopan, un inibitore del complemento di seconda generazione che previene le attività infiammatorie e protrombotiche. L'azienda sviluppa anche il nomacopan PASilato, in fase di sviluppo preclinico per il trattamento dell'atrofia geografica secondaria alla degenerazione maculare secca legata all'età, e la microangiopatia trombotica legata al trapianto di cellule staminali ematopoietiche (HSCT-TMA) combinata con il nomacopan, in fase di sviluppo clinico 3 per il trattamento della HSCT-TMA pediatrica.

Akari Therapeutics, Plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Akari Therapeutics con la sua capitalizzazione di mercato?
AKTX statistiche fondamentali
Capitalizzazione di mercato	US$15.54m
Guadagni(TTM)	-US$20.16m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.8x

Rapporto P/E

AKTX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
AKTX Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$20.16m
Guadagni	-US$20.16m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.69
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	-14.9%

Come si è comportato AKTX nel lungo periodo?

Vedi performance storica e confronto

AKTX Panoramica delle azioni

Analisi del rischio

Akari Therapeutics, Plc Concorrenti

OTCPK:HSTC

US$14.7m

NYSEAM:NNVC

US$19.7m

OTCPK:OPGN

US$12.5m

NasdaqCM:APRE

US$15.7m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Akari Therapeutics, Plc announced delayed 10-Q filing

Akari Therapeutics, Plc announced that it expects to receive $3.2 million in funding

Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics, Plc announced delayed 10-Q filing

New major risk - Share price stability

Recent updates

Akari Therapeutics, Plc announced delayed 10-Q filing

Akari Therapeutics, Plc announced that it expects to receive $3.2 million in funding

Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics, Plc announced delayed 10-Q filing

New major risk - Share price stability

Akari Therapeutics, plc Appoints Samir R. Patel as Interim President

Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024

Akari Therapeutics, Plc announced that it has received $0.5 million in funding

New major risk - Financial position

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

Akari Therapeutics Receives a Letter from the Listing Qualifications Staff of the Nasdaq Capital Market

New minor risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO).

Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics, Plc announced that it expects to receive $2 million in funding

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023

Akari Therapeutics, plc Grants Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer

Less than half of directors are independent

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics, plc Announces Updates on the Development of Long-Acting Pas-Nomacopan as A Potential Treatment for Geographic Atrophy

Akari Therapeutics, plc Announces Management Appointments

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2023

Akari Therapeutics, Plc Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric Hsct-Tma into Pivotal Part B and Addition of A New Pipeline Program Developing Nomacopan for Hsct-Tma in Adults

Price target decreased to US$4.00

Insufficient new directors

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of nomacopan for the Treatment of Pediatric HSCT-TMA

Akari Therapeutics Announces the Appointment of John F. Neylan, III as Executive Vice President, Chief Medical Officer

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Akari Therapeutics GAAP EPS of $0.00

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Akari Therapeutics, plc Announces That It Is Prioritizing Two Pipeline Programs

Insufficient new directors

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase Iii Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy

Patient completes course with Akari's stem cell transplant related complication treatment

Akari Therapeutics, Plc Appoints Melissa Bradford-Klug as Chief Operating Officer, Effective July 1, 2022

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2022

Akari Therapeutics, Plc Presents Results from the CASCADE and CORONET Studies in COVID-19

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology

Akari Therapeutics, Plc Presents Positive Results from Two Preclinical Studies of Its Lead Asset, Investigational Nomacopan

Insufficient new directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, plc Announces New Data Showing That Clinical Outcomes in U.S. Army Trauma Patients Correlate with Complement Activation

Akari Therapeutics, plc Announces Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

Akari Therapeutics, Plc announces FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Akari Therapeutics, Plc Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Akari Therapeutics reports FY results

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully